Celldex Therapeutics, Inc. (NASDAQ:CLDX) Releases Corporate Update


In late November, Celldex Therapeutics, Inc. (NASDAQ:CLDX) closed the acquisition deal of Kolltan Pharmaceuticals, Inc., bringing an innovative platform of antibodies targeting RTKs to its pipeline. Preclinical and clinical data indicate these candidates can help face tumor resistance mechanisms linked with current tyrosine kinase inhibitors and noted in people who didn’t respond to other cancer treatments.

The highlights

Updating on progress recorded in METRIC enrollment, Celldex reported that enrollment in the Phase IIb randomized study of glembatumumab vedotin in subjects with metastatic triple negative breast cancers has accelerated steadily over the last many months across the U.S., Australia, Canada and the European Union.

Considering the existing rate of registration continues, Celldex projects enrollment will be closed by September 30, 2017. The company also added third arm to glembatumumab vedotin Phase II trial in metastatic melanoma. Registration has been started in a glembatumumab vedotin plus checkpoint inhibitor arm in people who failed previous checkpoint treatment.

Enrollment continues in the varlilumab and glembatumumab vedotin arm, with results from this portion of the trial anticipated this year. Positive report from the single-agent arm of trial in people who had initially progressed on checkpoint treatment were presented at the ESMO Congress in October 2016.

The Phase II trial of Opdivo and varlilumab continues to enroll subjects across numerous indications. Celldex projects that data from the Phase I trial of Opdivo and varlilumab will be presented this year. It intends to complete registration across all cohorts in the Phase II portion of the trial in Q1 2018 and will work with BMS to showcase data from the trial at a future medical meeting.

Provided the move of varlilumab into an extensive Phase II trial with BMS, comprising in renal cell carcinoma, and measures to identify segments for cost-containment, the company has decided not to progress the varlilumab/Sutent® and the varlilumab/Tecentriq® combination trials in renal cell carcinoma to Phase II.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.